Arginine News and Research RSS Feed - Arginine News and Research

Arginine is considered a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed. For example, people with protein malnutrition, excessive ammonia production, excessive lysine intake, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, or sepsis may not have enough arginine. Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.

Arginine changes into nitric oxide, which causes blood vessel relaxation (vasodilation). Early evidence suggests that arginine may help treat medical conditions that improve with vasodilation, such as chest pain, clogged arteries (called atherosclerosis), coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and blood vessel swelling that causes headaches (vascular headaches). Arginine also triggers the body to make protein and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illnesses.

Arginine hydrochloride has a high chloride content and has been used to treat metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.
Researchers gain new insight into how motor neurons in the brain die during ALS

Researchers gain new insight into how motor neurons in the brain die during ALS

Researchers look to understand the causes of amyotrophic lateral sclerosis (ALS), in the hope of finding new ways to treat the disease. A new study published online today (December 17th) in the Cell Press journal Neuron shows that a common gene mutation in ALS generates a deadly protein that may cause the damage in the brain that leads to ALS. [More]
New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

A class of drug for treating arthritis - all but shelved over fears about side effects - may be given a new lease of life, following the discovery of a possible way to identify which patients should avoid using it. [More]
Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL). [More]
New treatment could halt growth of tumours in prostate cancer patients

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer. [More]
Discovery reveals promising target for treatment of end-stage heart failure

Discovery reveals promising target for treatment of end-stage heart failure

As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation. [More]
'Good' cholesterol turns 'bad' by sugar-derived substance

'Good' cholesterol turns 'bad' by sugar-derived substance

Scientists at the University of Warwick have discovered that 'good' cholesterol is turned 'bad' by a sugar-derived substance. [More]
Study identifies novel gene that controls nerve conduction velocity linked with MS

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity. [More]
Researchers discover how arginine starvation specifically kills cancer cells

Researchers discover how arginine starvation specifically kills cancer cells

Researchers at UC Davis, City of Hope, Taipai Medical University and National Health Research Institutes in Taiwan have discovered how a drug that deprives the cells of a key amino acid specifically kills cancer cells. [More]
Researchers discover novel biomarker that could help predict preeclampsia

Researchers discover novel biomarker that could help predict preeclampsia

University of Iowa researchers have discovered a biomarker that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as 6 weeks into the pregnancy. [More]
Scientists report first successful step toward vaccine that targets mutation in brain cancer

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system. [More]
SP Scientific announces LyoLearn program of free educational webinars

SP Scientific announces LyoLearn program of free educational webinars

SP Scientific has announced its Summer 2014 program of LyoLearn webinars. [More]
FDA accepts Symplmed's Prestalia NDA for hypertension treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance. [More]
Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder. [More]
TUSM scientists receive $11.5M grant to develop innovative treatments for heart failure

TUSM scientists receive $11.5M grant to develop innovative treatments for heart failure

Innovative treatments for heart failure are lacking, leaving the nearly six million Americans who suffer from the condition with little hope for a cure. [More]
Supermodel mouse reveals critical role played by unknown gene that regulates metabolism

Supermodel mouse reveals critical role played by unknown gene that regulates metabolism

A lean "Supermodel" mouse type has revealed the potentially critical role played by a largely unknown gene that regulates metabolism, findings that could provide new insight into diseases ranging from diabetes to obesity, a new study by UT-Southwestern Medical Center researchers suggests. [More]
Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

Scientists receive $2.3M grant to develop new technology to diagnose cancer, rheumatoid arthritis and colitis

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $2.3 million grant from the National Institute of General Medical Sciences of the National Institutes of Health to develop new technology to diagnose cancer, rheumatoid arthritis and colitis. [More]
ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. [More]

TSRI announces formation of Scripps Advance

The Scripps Research Institute (TSRI) today announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. [More]
Eating watermelon reduces blood pressure in overweight individuals

Eating watermelon reduces blood pressure in overweight individuals

Be sure to pick up a watermelon - or two - at your neighborhood farmers' market. It could save your life. [More]
Neuropeptide receptors could provide treatment target for chemoresistant SCLC

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results. [More]